Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


German Biotech MAB Discovery Inks Two Deals For Its Rabbit-Derived Antibody Technology

This article was originally published in The Pink Sheet Daily

Executive Summary

German antibody services company MAB Discovery – forged by former Roche employees – has had its rabbit antibody-derived technology validated by two collaborative agreements with pharma and biotech companies.

You may also be interested in...

In Private Equity Hands, PPD Could Seek More Deals

Two private equity firms’ agreement to acquire Pharmaceutical Product Development Inc. and take the company private is the latest and largest deal in a recent spate of PE activity among contract research organizations – and perhaps not the last, or even least.

PPD's Lee Babiss On Virtual R&D In China: An Interview With PharmAsia News (Part 1 Of 2)

Babiss speaks of the evolving relationships between pharmaceutical firms and CROs, including end-to-end virtualization of R&D.

Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts